Table 1 Descriptive statistics

Male / Female [n]

3 / 3

–

2 / 5

–

CIS / RRMS [n]

2 / 4

–

6 / 1

–

Age [years]

41 (28; 51)

–

51 (24; 54)

–

EDSS

Baseline

1.5 (0; 3)

–

1.5 (1; 2)

–

3 months

1.5 (0; 3)

1

1 (1; 1)

4

6 months

1.5 (0; 3)

1

1.25 (1; 1.5)

3

MSFC

Baseline

−0.10 (−0.87; 0.21)

–

0.18 (−1.27; 1)

–

3 months

−0.07 (− 0.30; 0.19)

1

0.47 (− 1.39; 0.87)

2

6 months

0.09 (− 0.27; 0.59)

2

0.08 (− 1.36; 0.64)

1

mfVEP Latency [ms]

Baseline

112.65 (107.1; 120.3)

–

95.8 (90.7; 108.1)

–

3 months

105.05 (92.8; 120.3)

2

120.3 (106; 120.3)

4

6 months

94.8 (92.8; 113.2)

1

109.1 (94.8; 120.3)

3

Δ = 6 months - Baseline

−15.7 (−19.3; 6.1)

1

8.15 (3.1; 24.5)

3

ffVEP P100 [ms]

Baseline

129.7 (119.2; 148.5)

–

122.1 (113.6; 145)

–

3 months

125 (108; 144.4)

3

113.18 (112.15; 114.2)

5

6 months

119.2 (93.9; 143.2)

1

109.8 (97.15; 110.4)

4

RNFLT [μm]

Baseline

94 (79; 116)

1

96 (84; 124)

1

3 months

88.5 (82; 112)

2

82 (77; 92)

3

6 months

83 (76; 110)

1

80.5 (75; 88)

3

Δ = 6 months - Baseline

−9 (−13; −6)

2

−6 (− 14; − 3)

4

GCIPLV [mm³]

Baseline

1.75 (1.46; 2.23)

1

1.7 (1.44; 2.13)

1

3 months

1.79 (1.67; 2.14)

2

1.65 (1.42; 1.89)

3

6 months

1.72 (1.45; 2.14)

1

1.68 (1.38; 1.89)

3

Δ = 6 months - Baseline

−0.065 (−0.09; −0.01)

2

−0.03 (−0.16; 0.01)

4

TMV [mm³]

Baseline

8.33 (8.14; 9.34)

1

8.36 (6.58; 9)

1

3 months

8.5 (8.12; 9.31)

2

8.52 (7.58; 8.71)

3

6 months

8.25 (8.03; 9.06)

1

8.46 (7.5; 8.7)

3

Δ = 6 months - Baseline

−0.28 (−0.3; −0.09)

2

−0.12 (− 0.41; − 0.11)

4

Sloan 100%

Baseline

32 (29; 39)

1

37 (35; 39)

5

[n letters]

3 months

35 (35; 39)

3

40 (40; 40)

6

6 months

40 (35; 44)

1

39 (29; 40)

4

Sloan 2.5%

Baseline

0 (0; 9)

1

2.5 (0; 5)

5

[n letters]

3 months

4 (3; 5)

3

2 (2; 2)

6

6 months

6 (0; 15)

1

1 (0; 13)

4

NEI-VFQ 39

Baseline

87.46 (76.63; 92.08)

3

88.71 (72.5; 94.28)

3

Composite Score

3 months

92.84 (81.40; 94.33)

3

87.52 (75; 97.05)

3

6 months

90.15 (78.30; 98.58)

3

74.60 (71.44; 84.85)

3

T2 Lesion Count

Baseline

34 (21; 64)

–

33 (15; 56)

–

[n]

6 months

34 (23; 37)

1

31.5 (14; 54)

3

Δ = 6 months - Baseline

2 (0; 2)

1

−1 (−2; 1)

3

T2 Lesion Volume

Baseline

3.57 (1.88; 5.5)

–

2.95 (0.91; 11.89)

–

[ml]

6 months

4.56 (2.11; 5.89)

1

2.77 (1.24; 12.56)

3

Δ = 6 months - Baseline

0.362 (0.11; 0.47)

1

0.31 (0.09; 0.67)

3

T2 New Lesion Count [n]

6 months - Baseline

2 (0; 3)

1

1.5 (1; 4)

3

T2 New Lesion Volume [ml]

6 months - Baseline

0.11 (0.00; 1.234)

1

0.226 (0.119; 1.085)

3

T2 Lesions with Increased Volume [n]

6 months - Baseline

12 (4; 18)

1

12.5 (4; 18)

3

T1 Gd-enhancing

Baseline

0 (0; 3)

1

0 (0; 6)

2

Lesions [n]

6 months

0 (0; 1)

1

0 (0; 2)

3

Δ = 6 months - Baseline

0 (0; 1)

2

0 (0; 0)

4